Novartis AG ( NVS ) just reported that its third-quarter net income fell to $2.1 billion from $6.9 billion. Sales rose 12% to 10.75 billion, which was in line with analyst estimates. The company’s drug pipeline registered steady numbers this quarter: Leukemia therapy Gleevec sales rose 15% to $950 m ...
Thanks for giving us the opportunity to guest post on our research concerning the relationship between free trade and intellectual property rights, set forth in our paper entitled How Innovative is Innovative Enough? Reflections on the Interpretation of Article 27 TRIPS from Novartis v. Union of Ind ...
Six leading drugmakers sent a letter Friday to U.S. accounting-rule lawmakers objecting to a proposed rule that would require companies to disclose estimate costs of all continuing litigation, the Wall Street Journal said Tuesday. According to Pfizer Inc, Merck & Co Inc, Eli Lilly & Co, Johnson & Jo ...
Novartis AG’s (Novartis) 1Q 08 sales growth was limited by weak performance (on the local currency basis) by its Pharmaceuticals division. However, the company’s Vaccines and Diagnostics (V&D) and Sandoz divisions recorded strong sales growth in 1Q 08. We expect revenues from the Pharmaceutical divi ...
